The aim of this systematic review was to synthesise the economic impact of rheumatoid arthritis (RA) on households, health systems, and society in low- and middle-income countries (LMICs). Electronic databases such as PubMed, Web of Science, and CINAHL were searched using keywords related to RA and cost of illness. Eligible studies were required to report RA-related costs, conducted in LMICs, and published in English. Quality appraisal of the included studies was carried out using the Newcastle-Ottawa Scale (NOS) for cohort studies. A narrative synthesis and meta-analysis of findings was carried out. A total of 5, 134 studies were initially identified for screening. After removing 1, 028 duplicates, 50 studies were selected for full-text review, and 15 met the eligibility criteria and were therefore included in the review. These studies, published between 2007 and 2024, were conducted in various countries, including Turkey (n=3), China (n=2), and one study each from Thailand, Hungary, Mexico, Colombia, Morocco, Pakistan, India, Romania, Brazil, and Argentina. Nine studies adopted a societal perspective, while six used a healthcare perspective. The total sample size was 218, 575 participants, with individual study sizes ranged from 62 to 209, 292. Average annual direct costs per patient ranged from US523 to US2837. 9, and indirect costs ranged from US81. 8 to US2463. 4. The pooled average annual cost for outpatients, inpatient and medical costs were US517. 72 (95% CI 3. 35 to 1, 032. 09), US543. 88 (95% CI US499. 51 - US588. 24), and US3, 379. 83 (95% CI US3, 137. 58 - US3, 622. 08, respectively. RA poses a significant economic challenge in LMICs, where limited healthcare resources and high treatment costs make care unaffordable for many. This review uniquely underscores that enhancing treatment access and optimising resource use can reduce both medical and productivity losses, improving patient outcomes and strengthening economic resilience.
Gebrye et al. (Mon,) studied this question.